Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD

Status:
Completed

Trial end date:
2008-01-02

Target enrollment:

Participant gender:

Assess the efficacy & tolerability of Vyvanse when children aged 6-12 years diagnosed with ADHD are dosed to optimal effect.

Phase 4

Shire

Lisdexamfetamine Dimesylate